Skip to main content
    G

    Galectin Therapeutics Inc (GALT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.91
    -0.11 (-3.64%)

    Market Cap: $304.57M

    Last updated: Nov 17, 2026 at 4:18 PM ET

    Galectin Therapeutics Inc (GALT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Galectin Therapeutics (GALT) has a market cap of $304.57M and an enterprise value of $326.07M. Its share count is up 39.59% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 7.06% above the market cap, as debt exceeds cash.

    Market Cap$304.57M
    Enterprise Value$326.07M
    Latest price (Nov 17, 2026)$2.91

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 36.05% in the quarter ended Sep 30, 2026 and grew 19.96% a year over 2 years.

    Shares Outstanding89.62M
    Shares Change (YoY)+39.59%
    Shares Change (QoQ)+36.05%
    Share Count Growth (2Y CAGR)+19.96%

    Price Statistics

    The stock is down 47.19% over 52 weeks and trades 18.94% below its 50-day average.

    Beta (1Y)1.11
    52-Week Change-47.19%
    1-Month Change-16.74%
    3-Month Change-20.71%
    6-Month Change+39.90%
    5-Year Change+4.73%
    10-Year Change+361.11%
    Total Return (1Y)-47.19%
    Total Return (3Y CAGR)+14.08%
    Total Return (5Y CAGR)+1.51%
    Return vs SPY (1Y)-64.55%
    Max Drawdown (1Y)-68.05%
    Max Drawdown (3Y)-79.99%
    Sharpe Ratio (1Y)-0.83
    Correlation with SPY (1Y)0.17
    50-Day Average$3.59
    200-Day Average$3.21
    52-Week Range$2.03 to $7.13
    RSI (14 Days)36.4
    Average Volume (20 Days)203.16K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.28x current liabilities.

    Current Ratio0.28x
    Quick Ratio0.28x
    Interest Coverage-2.47x

    Returns and Efficiency

    Return on invested capital is 671.12% over the last 12 months.

    Return on Assets (ROA)-178.26%
    Return on Invested Capital (ROIC)671.12%

    Scores

    GALT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit$12.00K
    Operating Income-$14.79M
    Pretax Income-$23.19M
    Net Income-$23.19M
    EBIT-$16.59M
    Reported EPS (TTM)-$0.34

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$11.71M
    Total Debt$33.21M
    Net Debt$21.50M
    Net Debt Per Share$0.24
    Working Capital-$33.50M
    Shareholder Equity-$35.16M
    Total Assets$13.01M
    Total Liabilities$46.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$14.61M
    FCF Per Share-$0.14
    Depreciation and Amortization$87.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    GALT does not pay a dividend.

    Buyback Yield-0.68%
    Shareholder Yield-0.68%

    Stock Splits

    The last split was a 1-for-6 reverse split on Mar 23, 2012.

    Last Split DateMar 23, 2012
    Split TypeReverse split
    Split Ratio1:6

    Peer Position

    Against 3 similar companies, GALT has the highest ROIC.

    ROIC671.12% vs -6.66% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -6.05% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GALT

    What is GALT's market cap?

    Galectin Therapeutics has a market cap of $304.57M. Its enterprise value, which adds debt and subtracts cash, is $326.07M.

    How many shares of GALT are outstanding?

    Galectin Therapeutics has 89.62M shares outstanding. The count is up 39.59% from a year earlier.

    Does GALT pay a dividend?

    No. Galectin Therapeutics does not pay a dividend.

    How much debt does GALT have?

    Galectin Therapeutics has $33.21M of total debt and $11.71M of cash and equivalents, a net debt position of $21.50M.